Sep 29, 2016 Cellectar Biosciences Announces New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma Learn More
Sep 19, 2016 Cellectar Biosciences to Present at Ladenburg Thalmann 2016 Healthcare Conference Learn More
Sep 12, 2016 Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant Learn More